Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform-Reference-Cited by-同舟云学术

Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform

Published:2023-11 Issue: Volume:34 Page:100741
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Zheng Bang,Tazare John,Nab Linda,Green Amelia CA.,Curtis Helen J.,Mahalingasivam Viyaasan,Herrett Emily L.,Costello Ruth E.,Eggo Rosalind M.,Speed Victoria^ORCID,Bacon Sebastian CJ.,Bates Christopher,Parry John,Cockburn Jonathan,Hester Frank,Harper Sam,Schaffer Andrea L.^ORCID,Hulme William J.,Mehrkar Amir,Evans Stephen JW.,MacKenna Brian,Goldacre Ben,Douglas Ian J.,Tomlinson Laurie A.

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference22 articles.

1. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19;Hammond;N Engl J Med,2022

2. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab;Gupta;N Engl J Med,2021

3. Nirmatrelvir use and severe covid-19 outcomes during the omicron surge;Arbel;N Engl J Med,2022

4. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study

5. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY;Green;BMJ Med,2023

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine;Infection and Drug Resistance;2024-09

2. Therapeutics Dataset from COVID-19 Medicine Delivery Units in England: an OpenSAFELY Data Report;Wellcome Open Research;2024-08-07

3. Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST);Journal of Infection and Public Health;2024-07

4. Quality control in SARS-CoV-2 RBD-Fc vaccine production using LC–MS to confirm strain selection and detect contaminations from other strains;Scientific Reports;2024-04-26

5. Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study;BMJ Open Respiratory Research;2024-04